“帝王缩减版”当道，而“帝国版”则在呜咽。（此翻译可能需结合特定语境理解其确切含义，原英文表述比较奇特，字面意思如上） - Suppr

Suppr

超能文献

EMPEROR-REDUCED reigns while EMPERIAL whimpers.

作者信息

Petrie Mark C, Lee Matthew M, Lang Ninian N

机构信息

BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

出版信息

Eur Heart J. 2021 Feb 11;42(6):711-714. doi: 10.1093/eurheartj/ehaa965.

DOI:10.1093/eurheartj/ehaa965

PMID:33367572

Abstract

摘要

相似文献

EMPEROR-REDUCED reigns while EMPERIAL whimpers.“帝王缩减版”当道，而“帝国版”则在呜咽。（此翻译可能需结合特定语境理解其确切含义，原英文表述比较奇特，字面意思如上）

Eur Heart J. 2021 Feb 11;42(6):711-714. doi: 10.1093/eurheartj/ehaa965.

Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.恩格列净治疗慢性心力衰竭患者的 EMPERIAL-Preserved 和 EMPERIAL-Reduced 试验的原理和设计。

Eur J Heart Fail. 2019 Jul;21(7):932-942. doi: 10.1002/ejhf.1486. Epub 2019 Jun 19.

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.恩格列净对射血分数降低和保留的心衰患者伴或不伴 2 型糖尿病运动能力和症状的影响。

Eur Heart J. 2021 Feb 11;42(6):700-710. doi: 10.1093/eurheartj/ehaa943.

Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.恩格列净在黑人与白人心力衰竭患者中的应用：EMPEROR汇总分析

Circulation. 2023 Jan 3;147(1):101-104. doi: 10.1161/CIRCULATIONAHA.122.062644. Epub 2022 Nov 7.

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用：EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。

Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.

Dapagliflozin Cut Risk of Worsening Heart Failure.达格列净降低心力衰竭恶化风险。

JAMA. 2020 Jan 28;323(4):301. doi: 10.1001/jama.2019.22087.

The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.DAPA-HF 试验：心力衰竭之战的重大胜利。

Cell Metab. 2019 Nov 5;30(5):847-849. doi: 10.1016/j.cmet.2019.10.008.

Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved.恩格列净在EMPEROR-Preserved研究中改善了射血分数保留的心力衰竭（HFpEF）的临床结局。

Nat Rev Cardiol. 2021 Nov;18(11):737. doi: 10.1038/s41569-021-00627-z.

Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.恩格列净对射血分数降低的慢性心力衰竭患者发病率和死亡率影响的评估：EMPEROR-Reduced 试验的原理和设计。

Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16.

EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial.EMPEROR-Reduced研究支持使用钠-葡萄糖协同转运蛋白2抑制剂治疗射血分数降低的心力衰竭患者：对EMPEROR-Reduced试验的评论

Eur Heart J. 2020 Oct 21;41(40):3881-3882. doi: 10.1093/eurheartj/ehaa783.

引用本文的文献

Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations.钠-葡萄糖协同转运蛋白2抑制剂与心血管系统：当前认识与未来展望

Heart Int. 2023 Dec 1;17(2):12-18. doi: 10.17925/HI.2023.17.2.12. eCollection 2023.

Empagliflozin: A Review in Symptomatic Chronic Heart Failure.恩格列净：在有症状的慢性心力衰竭中的评价。

Drugs. 2022 Nov;82(16):1591-1602. doi: 10.1007/s40265-022-01778-0. Epub 2022 Nov 14.

Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients.达格列净对射血分数降低的非糖尿病心力衰竭患者运动能力的影响。

J Clin Med. 2022 May 23;11(10):2935. doi: 10.3390/jcm11102935.

SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?钠-葡萄糖协同转运蛋白 2 抑制剂及其在心力衰竭中的作用机制——谜团是否已被揭开？

Curr Heart Fail Rep. 2021 Oct;18(5):315-328. doi: 10.1007/s11897-021-00529-8. Epub 2021 Sep 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验